Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway

BACKGROUND: Wogonin is an encouraging choice for clinical use owing to its potent anti-tumor and anti-inflammatory effects with the high safety profile. However, wogonin for targeted therapy of lymphoma was not well addressed. In this study, we focused on its anticancer effect alongside with the und...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xue, Liu, Ping, Zhang, Haijun, Li, Yuan, Salmani, Jumah Masoud Mohammad, Wang, Fei, Yang, Ke, Fu, Rong, Chen, Zhewei, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320633/
https://www.ncbi.nlm.nih.gov/pubmed/28222771
http://dx.doi.org/10.1186/s12885-017-3145-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320633/
https://www.ncbi.nlm.nih.gov/pubmed/28222771
http://dx.doi.org/10.1186/s12885-017-3145-4

Ejemplares similares